Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Incyte Corp
(NQ:
INCY
)
65.35
+0.19 (+0.29%)
Streaming Delayed Price
Updated: 3:04 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corp
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
December 02, 2022
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
November 17, 2022
From
Incyte
Via
Business Wire
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
November 07, 2022
From
Incyte and Mirati
Via
Business Wire
Expert Ratings for Incyte
October 18, 2022
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings
September 29, 2022
Via
Benzinga
Incyte Q2 Earnings Beat Estimates But Tightens FY22 Jakafi Sales Guidance
August 02, 2022
Via
Benzinga
Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 07, 2022
From
Incyte
Via
Business Wire
7 Cash-Rich Stocks to Buy for Peace of Mind
November 04, 2022
It pays to hold cash-rich stocks that can weather any storm because of their financial strength. Investors may want to watch these seven.
Via
InvestorPlace
2 Biotech Stocks That Could Make You Richer
November 04, 2022
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.
Via
The Motley Fool
More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
November 03, 2022
From
Incyte
Via
Business Wire
Recap: Incyte Q3 Earnings
November 01, 2022
Incyte (NASDAQ:INCY) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Incyte missed estimated earnings by...
Via
Benzinga
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
November 01, 2022
From
Incyte
Via
Business Wire
Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine
October 19, 2022
From
Incyte
Via
Business Wire
Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm'
October 17, 2022
Via
Benzinga
Incyte to Report Third Quarter Financial Results
October 11, 2022
From
Incyte
Via
Business Wire
2 Cathie Wood Stocks That Are Beating the Market This Year
October 07, 2022
One is doing much better than the other year to date, but they both have solid prospects ahead.
Via
The Motley Fool
Incyte Names New Member to Its Board of Directors
October 04, 2022
From
Incyte
Via
Business Wire
Incyte Acquires Villaris Therapeutics, Deepening Portfolio For Immune-Mediated Dermatologic Diseases
October 03, 2022
Via
Benzinga
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody
October 03, 2022
From
Incyte
Via
Business Wire
Death Cross Looms Over Incyte Investors
September 22, 2022
If history is any guide, there may be trouble ahead for shares of Incyte (NASDAQ:INCY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Via
Benzinga
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
September 15, 2022
Via
Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
August 26, 2022
Via
Benzinga
Incyte Gets FDA Nod For Hematologic Malignancies Candidate
August 26, 2022
The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ: INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with...
Via
Benzinga
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
August 26, 2022
From
Incyte
Via
Business Wire
Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
August 24, 2022
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
August 23, 2022
From
Incyte
Via
Business Wire
10 Most Oversold Stocks To Buy In August 2022
August 10, 2022
Looking for some oversold stocks to buy? Here's the 10 most oversold on the S&P 500 for August 2022.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
August 03, 2022
Via
Benzinga
Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled
August 02, 2022
Jakafi sales beat and the company raised its guidance. But another drug fell short.
Via
Investor's Business Daily
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
August 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.